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Introduction 
Acute splanchnic venous thrombosis is reported in 
5-15% of patients with acute splanchnic ischaemia. ~-~ 
In the earliest studies, primary thrombosis was 
reported in 60% of patients with acute splanchnic 
venous thrombosis9 Nowadays, the prevalence of 
primary acute splanchnic venous thrombosis has 
decreased to approximately 20% 4'6 and will probably 
decrease more in the future with the improved 
diagnosis and treatment of coagulopathies. 
In this report we describe the clinical course, our 
treatment protocol and the underlying coagulation 
disorders in three patients with acute splanchnic 
venous thrombosis. One of the coagulopathies has not 
previously been related to acute splanchnic venous 
thrombosis. 
Case Reports 
Case 1 
A 35-year-old man was admitted with a 2 week 
history of progressive physical depression, fatigue and 
fever. Two days before admission he complained of 
nausea and postprandial abdominal pain. He noted 
bloody diarrhoea once. There was a family history of 
thrombosis (grandfather). On physical examination, 
peritonitis was evident and a laparotomy was per- 
*Please address all correspondence to: R.H. Geelkerken, Department 
of Surger~ Medisch Spectrum Twente, P.O. Box 50.000, 7500 KA 
Enschede, The Netherlands. 
formed. The arterial splanchnic irculation was nor- 
mal but there was complete thrombosis of all veins in 
the mesentery of the small intestine including the 
central splanchnic veins. The entire small intestine 
was cyanotic, consistent with severe ischaemia, but no 
part of the intestine was necrotic and no resection was 
performed. In the IC-unit a hyperdynamic circulation 
was pursued with fluid challenge and dobutamine 
inotropic support guided by pulmonary artery pres- 
sure monitoring (cardiac index > 4.0 1/min/m2). 
Vasodilatation was achieved with ketanserin (4 rag/ 
h). Oxygen delivery (DO2) and oxygen consumption 
(VO2) were calculated using the standard formulae. In 
addition the patient was heparinised (APTT 60-90 s). 
Total parenteral feeding was started. Second and third 
look laparotomies were performed after 16 and 48 h. 
The severely compromised venous circulation of the 
small intestine appeared to be significantly 
improved. 
Initially, the oxygen extraction ratio and the oxygen 
consumption were high (VO2/DO 2 25-30%, VO2 
211-242 ml/min/m2). After 72 h the oxygen consump- 
tion decreased to normal levels (VO2/DO2 20-23%, 
VO2 131-197 ml/min/m2). The pharmacological cir- 
culatory support was gradually reduced. Warfarin 
and later fenprocoumon were administered (INR 
2.5-4.5) while treatment with heparin was 
discontinued. 
Extensive coagulation tests indicated that the 
patient had an antiphospholipid syndrome with high 
titre anti-cardiolipin antibodies (Table 1). Two years 
after the acute splanchnic venous thrombosis the 
patient is in excellent condition without intestine 
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Table 1. Acute splanchnic venous thrombosis; coagulation 
parameters of patient 1, 2 and 3. 
Case1 Case2 Case3 ranges 
APTT 26.4 59.7* 29.8 <33 s 
Prothrombin time 15.4i- 13.0 11.9 < 13.5 s 
Fibrinogen 2.4 3.8 3.7 2.0-4.5 g/1 
Protein C antigen 60-~ 87 135 >64%, >29%f 
Protein C activity n.t.~: 82 86 >66% 
Protein Santigen 69]- 195 106 > 67%, > 33%i- 
Antithrombin activity 106 68 48 > 80% 
Antithrombin antigen n.t. 48 47 > 80% 
APC-resistance n.t.{ n.t.$ 0.91 0.84-1.35 
Factor V Leiden§ absent present n.t. absent 
Anticardiolipin antibodies +++¶ n.t. n.t. absent 
*During heparin therapy. 
i-During cumarin therapy. 
~:Can ot be measured in patients who use anticoagulation therapy. 
§Mutation on factor V gene, associated with APC-resistance. 
¶High titre IgM anticardiolipin. 
n.t.: not tested. 
resection. Lifelong anticoagulation therapy with fen- 
procoumon is indicated. 
Case 2 
A 17-year-old man was admitted to a general hospital 
with a 1 week history of progressive abdominal pain 
and painless swelling of his right leg. One year 
previously, he had a deep venous thrombosis of his 
right leg; previous routine examinations had indicated 
no anatomical abnormalities or disorders of coagula- 
tion. The patient had received fenprocoumon for 6 
months. There was a family history of thrombosis 
(father). 
The diagnosis of acute splanchnic venous thrombo- 
sis was established at laparotomy. The arterial 
splanchnic circulation was normal but there was a 
complete thrombosis of all visible veins from the 
margin of the small intestine to the portal vein, 70 cm 
of the small intestine was necrotic and resected. The 
remaining 300 cm of the small intestine was severely 
ischaemic but not clearly necrotic. The patient was 
heparinised and a second look performed after 16 h at 
which the splanchnic venous thrombosis was seen to 
be progressive. Another 25 cm of the afferent small 
intestine was necrotic and consequently resected and 
an ileostomy was established on the afferent loop of 
the intestine. Following surgery the patient was 
transferred to our hospital. As with the patient 
described as case 1, protocolised supportive drug 
therapy was commenced on admission to the ICU. 
The protocol included gastric and ileum intestinal 
mucosal pH measurements (pHig and pHii) with a 
tonometer (TRIP TM nasogastric suction catheter and 
sigmoid catheter, Tonometrics, Inc., Worcester, U.S.A.). 
The patient received Ranitidine 50 mg intravenously 
four times a day. 7 The course of the oxygen extraction 
ratio, the oxygen consumption, the pHig, and the pHii 
are summarised in Fig. 1. Initially, a high oxygen 
extraction ratio and oxygen consumption was evident 
(VO2/DO2 28 %, VO 2 226 ml/min/m2).  The oxygen 
extraction ratio and the oxygen consumption dimin- 
ished after 6-8 h (VO2/DO 2 21%, VO2 190 ml /min /  
m2). Also, the initial low pHig (7.38) and the very low 
pHii (6.75) increased, indicating an improved intesti- 
nal mucosal circulation. After 30 h, the pHii gradually 
decreased followed by the pHig and later the oxygen 
consumption parameters (VO2/DO 2 9.8 %, VO 2 246 
ml/min/m2).  On the basis of this information, we 
performed a third laparotom)a The last 50 cm of the 
afferent intestine was necrotic and resected, but the 
remainder was clearly vital. Many patent peripheral 
and central veins were noticed. To close the efferent 
high output fistula, the efferent and afferent intestine 
was reanastomosed. Tonometers were positioned in 
the stomach and the ileum distal to the anastomosis. 
During the next 60 h the oxygen extraction ratio and 
256.7 
206.7 
~156.7 
> 
(a) 
106.7 ~ 
56.7 
6.7 J 
0 2O 
7.5 
b 
I 
40 60 80 100 120 
-132 
2O 
I 16 
140 
28 
cr 
24 "~ © 
> 
(b) 
7.4 
7.3 
7.2 
~ 7.1 
7.0 
6.9 
6.8 
6.'7 I I 1 I 1 I I 
0 20 40 60 80 100 120 140 
Hours afl:er admission i IC units 
Fig. 1. (a) Oxygen extraction ratio and oxygen consumption f case 
2 after admission i  the IC unit. (©) VO2; (@) VOz/DOu; (El) third 
laparotom35 (b) pHig and pHii of case 2 after admission i  the IC 
unit. (©) pHig; (@) pHiL 
Eur J Vasc Endovasc Surg Vol 13, February 1997 
Acute Splanchnic Venous Thrombosis 229 
the oxygen consumption diminished. The pHig and 
the pHii increased and stabilised at adequate levels 
(7.35). The supportive circulatory therapy was grad- 
ually reduced. Warfarin and later fenprocoumon were 
administered (INR 2.5-4.5) and the heparin was 
discontinued. Coagulation tests, both in the acute 
phase as some months after the thrombotic episode, 
indicated that the patient suffered from two coagula- 
tion disorders: antithrombin deficiency and activated 
protein C resistance (Table 1). The factor V Leiden 
mutation was also found in the mother of this patient, 
who otherwise did not have a history of thrombosis. 
His father had suffered from several thrombotic 
episodes before he died of intracerebral haemorrhage 
during anticoagulant treatment. It is very likely that 
his father carried the antithrombin deficiency. Eight- 
een months after the acute splanchnic venous throm- 
bosis the patient is in excellent health. Lifelong 
anticoagulation therapy with fenprocoumon is 
indicated. 
Case 3 
A 51-year-old man had a medical history of repeated 
deep venous thrombosis of his lower limbs 8 years 
previously. A low antithrombin level was found in 
1986 and lifelong fenprocoumon was advised. For 5 
years the patient suffered from portal hypertension 
with liver cirrhosis of unknown origin. A month prior 
to admission, he had an episode of severe bleeding of 
grade IV oesophageal varices and the fenprocoumon 
was stopped. He was admitted with haematemesis 
and signs of peritonitis. Sclerotherapy of the oeso- 
phageal varices was performed successfully and 
laparotomy was performed. The diagnosis of acute 
splanchnic venous thrombosis was established. Coag- 
ulation tests again showed a low antithrombin, 
whereas all other clotting tests were completely 
normal (tests not performed during heparin treat- 
ment) (Table 1). This, as well as the fact that the 
antithrombin activity had been low years earlier, made 
a congenital antithrombin deficiency most likely. 
There was a venous thrombosis of a 50 cm segment of 
the ileum together with a partly necrotic intestine. The 
remaining part of the small intestine was ischaemic, 
and partial thrombosed veins were evident. The 
central splanchnic veins and the portal vein were 
completely thrombosed. The necrotic segment of the 
intestine was resected and anastomosis performed. We 
started supportive therapy in the IC-unit following the 
same protocol as was used in case one, including 
measurements of the mucosal pH of the ileum with a 
tonometer. The course of the oxygen extraction ratio, 
the oxygen consumption, and the pHii are sum- 
marised in Fig. 2. On admission, a high oxygen 
extraction ratio and a normal oxygen consumption 
(VO2/DO 2 46%, VO2 128 ml/min/m2), due to an 
initially low haemoglobin concentration (3.5 mmol/1) 
were recorded. During the supportive therapy the 
oxygen extraction ratio diminished and the oxygen 
consumption i creased, partially due to an improved 
oxygen delivery (blood transfusions). Also, the low 
pHii increased (from 7.06 to 7.36), indicating 
improved mucosal circulation. A second look lapar- 
otomy was performed after 18 h. The remaining 
intestine was obviously vital, the anastomosis was 
adequate. On the eighth day after admission, (pHii 
decreased to 7.03), a third laparotomy was performed. 
The intestine was vital and the peripheral splanchnic 
veins patent. Increasing instability of the patient was 
caused by persistent oesophageal variceal bleeding. 
The heparin was stopped and he subsequently under- 
went repeated sclerotherapy and mesocaval shunting. 
To reduce the chance of repeated acute splanchnic 
venous thrombosis, the antithrombin deficiency was 
supplemented with antithrombin concentrate (25-50 
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units per kg, Kabi, Stockholm, Sweden). On the 
fifteenth day after admission, he developed multi- 
organ failure and died. Autopsy revailed partial 
thrombosis of several main splanchnic veins, the 
splenic vein and the portal vein. The intestine was 
vital the anastomosis was sufficient. 
Discussion 
In the present report some new developments in the 
management of acute splanchnic venous thrombosis 
are discussed. First is the use of tonometry to monitor 
the intestinal circulation of these patients. Second is 
the evidence that antiphospholipid syndrome and 
factor V Leiden can be implicated in the aetiology of 
acute splanchnic venous thrombosis. Third, the use of 
antithrombin concentrate therapy when acute 
splanchnic venous thrombosis is accompanied by 
bleeding oesophageal varices and antithrombin defi- 
ciency has not previously been reported. Acute 
splanchnic venous thrombosis, in spite of its name, 
develops gradually, s'9 Ultimately it can progress to 
acute splanchnic ischaemia, manifesting as peritonitis. 
Abdominal symptoms, which are the main cause of 
complaint in 80-90 % of patients, 4"1° may be present 
4 11 for anything from a few days to a month. Symptoms 
first manifested in the three patients described above 
1, 2 and 7 days prior to admission, respectively. The 
reason for this prolonged course of development is
that acute splanchnic venous thrombosis rarely causes 
intestinal necrosis or perforation. 12 The enormous 
venous reserve of the splanchnic bed protects the 
intestines from early necrosis. Timely heparinisation 
prevents progression of the thrombosis and may be 
life-saving, 13 while cardiac output should be optim- 
alised and reactive splanchnic vasoconstriction 
treated. 1° To this end we administer ketanserin intra- 
venously, 14 thus avoiding the necessity for prolonged 
selective catheterisation of the superior mesenteric 
artery. In our experience, confirmed by others, 6'1°'15 
this aggressive supportive therapy carries a good 
prognosis and resection should therefore be limited to 
intestine that is clearly necrotic. Monitoring the 
subsequent progress of a threatened but not yet 
necrotic intestine following laparotomy can present 
problems. Relaparotomy is not really an option; the 
information gained applies only to conditions at the 
moment of operation, and there is a limit to the 
number of laparotomies which can be performed. 
Tonometry on the other hand can provide a virtually 
continuous tream of information about the condition 
of the affected bowel. Estimating the intramucosal pH 
with a tonometer is an indirect method of measuring 
the metabolism of the gut. 16 A fall in pHi below 
normal limits is an early indicator of the presence of 
anaerobic metabolism which is, in turn, a function of 
local mucosal ischaemiaF In our second patient here 
was an early fall in pHii, followed by pHig and, some 
30 h after admission to the ICU, increased oxygen 
consumption, all attributable to local necrosis of the 
small intestine. The fall in pHii in our third patient 8 
days after admission was probably caused by bleeding 
esophageal varices. Tonometric monitoring of the 
intestinal circulation with rapid intervention on reduc- 
tion of the pH appears to open new perspectives in the 
treatment of acute splanchnic venous thrombosis. 
A substantial proportion of patients with primary 
acute splanchnic venous thrombosis are likely to have 
an underlying thrombophilic disorder. Is Deficiencies 
of antithrombin, protein C, and S, dysplasminogenae- 
mia, hypoplasminogenaemia andpolycythaemia vera 
19 have all been reported in this connection. Of our 
three patients, one had a high anticardiolipin antibody 
titre, one antithrombin deficiency and one both antith- 
rombin deficiency and activated protein C resistance 
(factor V Leiden). The antiphospholipid syndrome has 
been described as a disorder characterised by a history 
of arterial or venous thrombosis and recurrent fetal 
death in the presence of pathological antibodies (IgG, 
20 21 IgM or both) to phospholipids. ' It may manifest 
either as primary disease, or secondary to SLE 22 or 
other autoimmune, infectious or neoplastic pathology. 
Antibodies to phospholipids can be demonstrated in 
vitro by means of clotting tests (lupus anticoagulant) 
or the presence of anticardiolipin antibodies. There is, 
however, some controversy about the clinical sig- 
nificance of the presence of anticardiolipin antibodies 
and their relationship to the lupus anticoagulant, 23 
especially as the primary antiphospholipid syndrome 
includes a wide variety of clinical features and 
laboratory findings. Our patient registered high titre 
IgM anticardiolipin antibodies on two occasions 
shortly after the acute splanchnic venous thrombosis 
in the absence of any demonstrable underlying dis- 
ease. The lupus anticoagulant test was, however, 
negative on both occasions. Nevertheless, the presence 
of anticardiolipin antibodies in a patient suffering 
from acute splanchnic venous thrombosis is highly 
24 25 suggestive, ' and seems the most likely explanation 
for his condition. 22 
Both antithrombin deficiency and resistance to 
activated protein C were present in the second patient. 
Activated protein C inhibits the activated procoagu- 
lant protein factors Va and VIIIa. Recently Dahlback et 
26 al. reported a number of patients in whom the 
addition of activated protein C to plasma did not 
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result in the expected prolongation of the activated 
partial thromboplastin time (APTT). The cause 
appears to be a mutation in the activated protein C 
cleavage-site in factor V (factor V Leiden).27 The defect 
seems to be quite common, indeed the most common 
inherited cause of thrombosis, with incidences of 3 % 
in healthy individuals, 20 % in unselected patients 
presenting for the first time with thrombosis and 50 % 
in those with unexplained familial thrombosis. 2s'z9 
The risk of venous thrombosis is seven times that in 
normal individuals, 2s although activated protein C 
resistance has not previously been reported in associa- 
tion with acute splanchnic venous thrombosis. 
Antithrombin is a naturally occurring anticoagulant 
which inhibits thrombin, factor Xa and other serum 
proteases. Antithrombin deficiency may be congenital 
(autosomal dominant disorder) or acquired as a result 
of, for instance, nephrotic syndrome. In patients who 
suffer from the congenital form normal antithrombin 
activity is reduced by roughly 50%. Incidence of 
antithrombin deficiency has been estimated at seven 
per 100 000 in the population as a whole, 3° but rises to 
4% of patients with thrombosis. 3a There is a more 
marked thrombotic tendency than in protein C and S 
deficiencies, with a cumulative risk of 10% up to 15, 
50% up to 24 and 85% up to 50 years of age. 31"32 
Coumarin anticoagulant therapy is usually effective 
in preventing venous thrombosis. However, the risk of 
coumarin-induced bleeding is about 3% per year, 33 
which makes the cumulative risk of long-term treat- 
ment, in our opinion, unacceptably high. For this 
reason we avoid chronic anticoagulant therapy with 
coumarins in patients who have suffered an isolated 
thrombotic episode. Repeated thromboses, a life- 
threatening episode, or thrombosis associated with a 
thrombophilic disorder, however, carry a sufficiently 
high risk of recurrence as to outweigh the threat of a 
haemorrhage. Thus our second patient, although he 
had suffered a previous deep vein thrombosis of the 
leg, received only temporary anticoagulant therapy 
after this episode, because no underlying disorder of 
coagulation could be found. 
Our third patient placed us in something of a 
dilemma. Heparin, which was essential for the treat- 
ment of his acute splanchnic venous thrombosis 
caused haemorrhage from his oesophageal varices. 
This was so severe that the heparin treatment had to 
be abandoned. An alternative had to be found, 
otherwise there was a danger that the acute splanchnic 
venous thrombosis would progress. It was decided to 
commence treatment with antithrombin concentrate 34 
(Kabi, Stockholm, Sweden). It was possible to achieve 
more than 80% antithrombin activity with 2000-4000 
units (25-50 units per kg) per day. Unfortunately after 
6 days of therapy he developed multi-organ failure 
and died, so that we were unable to evaluate the 
outcome of the therapy. Nevertheless this was proba- 
bly one of the rare cases which justify the use of 
antithrombin concentrate in the treatment of 
thrombosis. 
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